Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation ...

New evidence compares micro-ultrasound and MRI fusion biopsy for detecting clinically significant prostate cancer. Find out ...

Anyone discouraged by the continued absence of a prostate cancer screening programme, the difficulties in getting a clear ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U ...

Ultra-high-field 5 T MRI improves prostate cancer image quality and diagnostic performance versus 3 T. Learn more about its potential.

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

A new imaging approach developed by researchers at Heriot-Watt University has shown "extremely encouraging" results in early-stage clinical trials on prostate cancer at the Western General Hospital in ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Imaging has an established role in the local and distant staging of prostate cancer. However, it is increasingly demonstrating the ability to identify focal areas of tumor within the prostate gland, ...

An article about the importance of PSA testing for early detection and treatment of prostate cancer ...